J. Walz to Prostate-Specific Antigen
This is a "connection" page, showing publications J. Walz has written about Prostate-Specific Antigen.
Connection Strength
0.516
-
Bjerner J, Bratt O, Aas K, Albertsen PC, Foss? SD, Kv?le R, Lilja H, M?ller C, M?ller S, Stensvold A, Thomas O, R?e OD, Vickers A, Walz J, Carlsson SV, Oldenburg J. Baseline Serum Prostate-specific Antigen Value Predicts the Risk of Subsequent Prostate Cancer Death-Results from the Norwegian Prostate Cancer Consortium. Eur Urol. 2024 Jul; 86(1):20-26.
Score: 0.206
-
Walz J, Chun FK, Klein EA, Reuther A, Graefen M, Huland H, Karakiewicz PI. Risk-adjusted hazard rates of biochemical recurrence for prostate cancer patients after radical prostatectomy. Eur Urol. 2009 Feb; 55(2):412-19.
Score: 0.076
-
Walz J, Suardi N, Hutterer GC, Perrotte P, Gallina A, B?nard F, Valiquette L, McCormack M, Graefen M, Montorsi F, Karakiewicz PI. Lower urinary tract symptoms affect one-third of men in a prostate cancer screening population. J Endourol. 2008 Feb; 22(2):369-76.
Score: 0.071
-
Ahyai SA, Graefen M, Steuber T, Haese A, Schlomm T, Walz J, K?llermann J, Briganti A, Zacharias M, Friedrich MG, Karakiewicz PI, Montorsi F, Huland H, Chun FK. Contemporary prostate cancer prevalence among T1c biopsy-referred men with a prostate-specific antigen level < or = 4.0 ng per milliliter. Eur Urol. 2008 Apr; 53(4):750-7.
Score: 0.070
-
Gallina A, Jeldres C, Chun FK, Shariat SF, Briganti A, Walz J, Roehrborn CG, Saad F, Huland H, Graefen M, Montorsi F, Karakiewicz PI. Prediction of pathological stage is inaccurate in men with PSA values above 20 ng/mL. Eur Urol. 2007 Nov; 52(5):1374-80.
Score: 0.066
-
Joniau S, Spahn M, Briganti A, Gandaglia G, Tombal B, Tosco L, Marchioro G, Hsu CY, Walz J, Kneitz B, Bader P, Frohneberg D, Tizzani A, Graefen M, van Cangh P, Karnes RJ, Montorsi F, van Poppel H, Gontero P. Pretreatment tables predicting pathologic stage of locally advanced prostate cancer. Eur Urol. 2015 Feb; 67(2):319-25.
Score: 0.027